Potassium drug may unlock better kidney and heart protection
NCT ID NCT06256991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether patiromer, a drug that lowers potassium, allows people with moderate-to-severe chronic kidney disease to safely increase their dose of a common blood pressure medication (irbesartan). The goal is to see if this leads to better kidney protection and lower blood pressure. About 44 adults will take patiromer or a placebo for 12 weeks each, with the order randomly assigned.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Groningen
RECRUITINGGroningen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Chatbot could put blood pressure control in Patients' hands
- Blood test could predict who faces rapid kidney decline in diabetes
- Can a 5-Step chat help tame high blood pressure?